Effect of Resveratrol on Blood Lipid Levels in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Obesity (Silver Spring). 2019 Jan;27(1):94-102. doi: 10.1002/oby.22348.

Abstract

Objective: Few studies have considered the effect of resveratrol on blood lipid levels, and the results of these studies are inconsistent. In this study, the first meta-analysis on the effect of resveratrol on blood lipid levels in patients with type 2 diabetes was conducted.

Methods: This study used keywords such as type 2 diabetes, total cholesterol, triglyceride (TG), high-density lipoprotein, low-density lipoprotein, and resveratrol and their abbreviations, free words, and related words to search PubMed, Cochrane Library, and Embase. The Cochrane risk of bias tool was used to evaluate the risk of bias, and Review Manager 5.3 and Stata 13.0 were used for data merging and statistical analysis.

Results: Ten randomized controlled trials involving a total of 363 patients with type 2 diabetes were included in the analysis. The results show that longer resveratrol intervention time (≥6 months) can reduce TG levels. But resveratrol increased total cholesterol in patients within obesity range. In type 2 diabetes patients with obesity and in those who took lipid-lowering drugs, resveratrol increased low-density lipoprotein levels.

Conclusions: Resveratrol can improve TG in patients with type 2 diabetes.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / pathology
  • Humans
  • Hypolipidemic Agents / pharmacology
  • Hypolipidemic Agents / therapeutic use*
  • Lipids / blood*
  • Resveratrol / pharmacology
  • Resveratrol / therapeutic use*

Substances

  • Hypolipidemic Agents
  • Lipids
  • Resveratrol